Company: LIMN
Filing Date: 2025-07-25
Form Type: CORRESP
Source: 0001104659-25-070940
Chunk: 0

Company: Liminatus Pharma, Inc.
Filing Date: 2025-07-25
Form: CORRESP
Chunk 0
---
| Giovanni Caruso    
 Partner            
 345 Park Avenue    
 New York, NY 10154 | Direct   212.407.4866   
 Main     212.407.4000   
 Fax        212.937.3943 
 gcaruso@loeb.com        |

July 25, 2025

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

| Attention: | Tyler Howes    |
|            | Tim Buchmiller |

| Re: | Liminatus Pharma, Inc.             
 Registration Statement on Form S-1 
 Filed June 24, 2025                
 File No. 333-288289                |

Ladies and Gentlemen:

On behalf of our client, Liminatus
Pharma, Inc., a Delaware corporation (the “Company”), we respond to the comments of the staff of the Division of Corporation
Finance of the U.S. Securities and Exchange Commission (the “Staff”) with respect to the above-referenced Registration Statement
on Form S-1 filed on June 24, 2025, contained in the Staff’s letter dated July 3, 2025 (the “Comment Letter”).

The Company has filed via
EDGAR Amendment No. 1 to the Registration Statement on Form S-1 (the “Amendment”), which reflects the Company’s responses
to the comments received by the Staff and certain updated information. For ease of reference, each comment contained in the Comment Letter
is printed below and is followed by the Company’s response. All page references in the responses set forth below refer to the page
numbers in the Amendment.

Registration Statement on Form S-1

General

| 1. | We note that you are registering 1,750,000 shares of common stock issuable to Cantor in settlement                                           
 of $7.0 million of deferred underwriter fees. Please revise, wherever appropriate, to explain how the number of shares issuable to Cantor    
 was calculated. In this regard, we note that the amendment to your Form S-4 filed on August 9, 2024 indicated that 700,000 shares would      
 be issuable to Cantor in settlement of these deferred underwriting fees, subject to adjustment based on the five day volume-weighted average 
 price prior to the filing of a resale registration statement covering such shares, and it appears